Scoop has an Ethical Paywall
Merck Statement on COX-2 Inhibitors
Friday 29 April 2005
Alister Brown, managing director of Merck Sharp & Dohme New Zealand (MSD NZ), made the following comments in response to today’s announcement by the Ministry of Health that COX-2 inhibitors will remain available in New Zealand:
“At this time, Medsafe has issued new prescribing advice for selective Cox-2 inhibitor medicines, including ARCOXIA® (etoricoxib).
“We welcome the decision by Medsafe that will allow ARCOXIA to remain as a prescribing option in New Zealand. We are reviewing the actions of Medsafe and look forward to our discussions with the agency with respect to ARCOXIA.
“MSD NZ is continuing studies to further establish the long-term cardiovascular and overall safety profile of ARCOXIA.”
ENDS
Advertisement - scroll to continue reading
NZEI Te Riu Roa: NZEI Te Riu Roa Joins Calls To Restore Cut To Pasifika Early Literacy Project
NZ Opera: New Zealand Opera To Celebrate 25 Years In 2025
NZ Rugby League: Kiwi Ferns Ready To Defend Their Pacific Championships Title In Thrilling Final
PHARMAC: Newly Funded Medicine To Benefit 110 More People With Thyroid, Liver, And Kidney Cancer
Plunket: Plunket’s New One Stop Community Hub Opens In Dunedin
NZ College of Public Health Medicine: Treaty Principles Bill Will Harm Māori Health And Fuel Racial Division